Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1999 3
2003 2
2004 2
2005 3
2006 3
2007 3
2008 3
2009 4
2010 2
2011 1
2012 1
2013 2
2015 2
2016 4
2017 4
2018 2
2019 2
2020 1
2021 3
2022 3
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
Morschhauser F, Nastoupil L, Feugier P, Schiano de Colella JM, Tilly H, Palomba ML, Bachy E, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Le Gouill S, Daguindau N, Guidez S, Pica GM, García-Sancho AM, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Kalung W, Sehn LH, Izutsu K, Cartron G, Gkasiamis A, Crowe R, Xerri L, Fowler NH, Salles G. Morschhauser F, et al. J Clin Oncol. 2022 Oct 1;40(28):3239-3245. doi: 10.1200/JCO.22.00843. Epub 2022 Aug 10. J Clin Oncol. 2022. PMID: 35947804 Free PMC article.
Cost-effectiveness of rituximab in follicular lymphoma.
Johnston KM, Bolbocean C, Connors J, Peacock S. Johnston KM, et al. Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):569-77. doi: 10.1586/erp.12.57. Epub 2012 Nov 11. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 23140274 Review.
Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta-analysis of randomized trials.
Chu Y, Liu Y, Yu Z, Zhan L, Lu T, Jiang Y, Fang X, Zhou X, Wang X. Chu Y, et al. Cancer. 2024 Apr 1;130(7):1072-1082. doi: 10.1002/cncr.35137. Epub 2023 Dec 2. Cancer. 2024. PMID: 38041532
Considering other regimens, although an extended course of rituximab maintenance and consolidation therapies presented PFS benefits compared with standard rituximab maintenance, they were also associated with higher toxicity. ...
Considering other regimens, although an extended course of rituximab maintenance and consolidation therapies presented PFS benefits c …
Management of elderly patients with malignant lymphoma.
Miyazaki K. Miyazaki K. Jpn J Clin Oncol. 2022 Jul 8;52(7):690-699. doi: 10.1093/jjco/hyac056. Jpn J Clin Oncol. 2022. PMID: 35435235
The outcome for older patients is poorer than that for younger patients. A poor prognosis is associated with heterogeneity and consists of physical function, performance status, poor nutritional status and various comorbidities. ...Follicular lymphoma is the second most co …
The outcome for older patients is poorer than that for younger patients. A poor prognosis is associated with heterogeneity and consis …
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Watanabe T, Matsuno Y, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, Shimada K, Asagoe K, Yamaguchi M, Ando K, Ogura M, Kuroda J, Suehiro Y, Tsukasaki K, Tobinai K, Nagai H. Watanabe T, et al. Hematol Oncol. 2024 May;42(3):e3272. doi: 10.1002/hon.3272. Hematol Oncol. 2024. PMID: 38595316 Clinical Trial.
Thus, identifying factors that predict shorter survival is essential to stratify treatment and prolong the survival of patients with FL. ...However, an analysis limited to the first 10 years revealed that the prognostic factors elucidated from the longer-term analys …
Thus, identifying factors that predict shorter survival is essential to stratify treatment and prolong the survival of patients with …
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW, Büyükkaramikli NC, Riemsma R, Fayter D, Armstrong N, Wei CY, Huertas Carrera V, Misso K, Worthy G, Kleijnen J, Corro Ramos I. Thielen FW, et al. Pharmacoeconomics. 2019 Aug;37(8):975-984. doi: 10.1007/s40273-018-0740-4. Pharmacoeconomics. 2019. PMID: 30547368 Free PMC article. Review.
All of these adjustments did not exceed 30,000 per QALY gained and therefore the use of obinutuzumab for patients with advanced FL and a Follicular Lymphoma International Predictive Index (FLIPI) score of two or more could be recommended....
All of these adjustments did not exceed 30,000 per QALY gained and therefore the use of obinutuzumab for patients with advanced FL and a Fol …
Follicular lymphoma-related colitis resembling ulcerative colitis.
Zenda T, Nakagawa N, Maruyama H, Endo T, Higashi K, Yamamoto J, Komai K, Watanabe K, Araki I. Zenda T, et al. Clin J Gastroenterol. 2017 Apr;10(2):147-153. doi: 10.1007/s12328-016-0708-x. Epub 2016 Dec 24. Clin J Gastroenterol. 2017. PMID: 28013449
The patient was ultimately diagnosed with follicular lymphoma (stage IV A, grade 1) based on a pathological examination of the neck lymph nodes, iliac bone marrow, and colon. After six courses of chemotherapy (R-CHOP), (18)F-FDG-PET/CT confirmed complete remission of the l …
The patient was ultimately diagnosed with follicular lymphoma (stage IV A, grade 1) based on a pathological examination of the neck lymph no …
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Boccomini C, Ladetto M, Rigacci L, Puccini B, Rattotti S, Volpetti S, Ferrero S, Chiarenza A, Freilone R, Novo M, Corradini P, Nassi L, Rusconi C, Stelitano C, Bolis S, Marina Liberati A, Tucci A, Baldini L, Balzarotti M, Evangelista A, Ciccone G, Vitolo U. Boccomini C, et al. Br J Haematol. 2021 Apr;193(2):280-289. doi: 10.1111/bjh.17283. Epub 2021 Jan 21. Br J Haematol. 2021. PMID: 33476434 Clinical Trial.
A phase II, multicentre, single arm trial was conducted in this setting with a brief chemoimmunotherapy regimen. Treatment consisted in four monthly courses of rituximab, bendamustine and mitoxantrone (R-BM) followed by 4 weekly rituximab as consolidation; rituximab mainte …
A phase II, multicentre, single arm trial was conducted in this setting with a brief chemoimmunotherapy regimen. Treatment consisted in four …
Autologous transplant of follicular lymphoma in the era of rituximab.
Witzens-Harig M, Dreger P. Witzens-Harig M, et al. Leuk Lymphoma. 2010 Jun;51(6):967-74. doi: 10.3109/10428191003793341. Leuk Lymphoma. 2010. PMID: 20443675 Review.
Taken together, the absence of an overall survival benefit, the risk of secondary malignancies, and the remarkably good prognosis of patients who receive rituximab and ASCT as salvage therapy in the relapse situation make the use of ASCT as initial therapy difficult to jus …
Taken together, the absence of an overall survival benefit, the risk of secondary malignancies, and the remarkably good prognosis of …
49 results